Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

85.25CHF
6:23am EST
Change (% chg)

CHF-0.80 (-0.93%)
Prev Close
CHF86.05
Open
CHF86.00
Day's High
CHF86.55
Day's Low
CHF84.20
Volume
56,207
Avg. Vol
51,863
52-wk High
CHF87.35
52-wk Low
CHF61.20

Select another date:

Mon, Feb 20 2017

BRIEF-Basilea Pharmaceutica FY 2016 net loss narrows to CHF 51.3 million

* In 2017, Basilea will further advance clinical development of its oncology drug candidates and expects to complete dose-escalation in bal101553's phase 1/2a studies and bal 3833's phase 1 study

BRIEF-Basilea antifungal Cresemba (isavuconazole) launched in France

* Says basilea's antifungal cresemba (isavuconazole) launched in france Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

BRIEF-MedCap unit to distribute Basilea's products in Scandinavia

* Says its unit Unimedic Pharma AB has entered into licensing and distribution agreement with Basilea Pharmaceutica Ltd

BRIEF-Basilea announces distribution agreement with Unimedic for Cresemba and Zevtera in Nordic Countries

* Announces distribution agreement with unimedic for Cresemba (isavuconazole) and Zevtera (ceftobiprole) in Nordic Countries Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea announces partnership for antifungal isavuconazole in Japan

* Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma

BRIEF-Basilea: supply, distribution and license agreement with GBT

* Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA (isavuconazole) and Zevtera (ceftobiprole) in Latin America

BRIEF-Basilea Pharmaceutica: phase 1/2a clinical study with oncology drug candidate

* Starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date:

More From Around the Web